Wells Fargo Initiates Coverage On Alnylam Pharmaceuticals with Equal-Weight Rating, Announces Price Target of $171
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Tiago Fauth has initiated coverage on Alnylam Pharmaceuticals (NASDAQ:ALNY) with an Equal-Weight rating and set a price target of $171 for the company's stock.

December 08, 2023 | 10:46 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Wells Fargo initiated coverage on Alnylam Pharmaceuticals with an Equal-Weight rating and a price target of $171, which may influence investors' perceptions and the stock's market performance.
The initiation of coverage by Wells Fargo with an Equal-Weight rating suggests a neutral outlook on the stock, indicating that the stock is adequately valued at its current price. The price target of $171 provides a benchmark for investors but does not imply significant upside or downside, hence the neutral score. The relevance is high as the news is directly about ALNY. The importance is significant as analyst ratings can influence market perception, but not critical as the rating is neutral. The confidence level is high due to the direct impact analyst ratings tend to have on stock performance, although the exact market reaction can vary.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100